Your browser doesn't support javascript.
loading
Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammato ry Diseases.
Rajana, Vinod Kumar; Penumaka, Sudha Madhavi; Saritha, Cevella; Ravichandiran, Velayutham; Mandal, Debabrata.
Afiliación
  • Rajana VK; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.
  • Penumaka SM; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.
  • Saritha C; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.
  • Ravichandiran V; Department of Natural Products, National Institute of Pharmaceutical Education and Research, Kolkata, 700054, India.
  • Mandal D; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.
Antiinflamm Antiallergy Agents Med Chem ; 22(4): 273-275, 2023.
Article en En | MEDLINE | ID: mdl-37997806
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biosimilares Farmacéuticos Idioma: En Revista: Antiinflamm Antiallergy Agents Med Chem Año: 2023 Tipo del documento: Article País de afiliación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biosimilares Farmacéuticos Idioma: En Revista: Antiinflamm Antiallergy Agents Med Chem Año: 2023 Tipo del documento: Article País de afiliación: India